XBI vs. BIB
Compare and contrast key facts about SPDR S&P Biotech ETF (XBI) and ProShares Ultra Nasdaq Biotechnology (BIB).
XBI and BIB are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010. Both XBI and BIB are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: XBI or BIB.
Key characteristics
| XBI | BIB | |
|---|---|---|
| YTD Return | -2.20% | -7.77% |
| 1Y Return | 9.55% | -4.16% |
| 3Y Return (Ann) | -13.87% | -15.89% |
| 5Y Return (Ann) | 0.31% | 0.52% |
| 10Y Return (Ann) | 7.72% | 3.60% |
| Sharpe Ratio | 0.23 | -0.21 |
| Daily Std Dev | 28.31% | 33.36% |
| Max Drawdown | -63.89% | -67.24% |
| Current Drawdown | -49.78% | -52.76% |
Correlation
The correlation between XBI and BIB is 0.91, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
XBI vs. BIB - Performance Comparison
In the year-to-date period, XBI achieves a -2.20% return, which is significantly higher than BIB's -7.77% return. Over the past 10 years, XBI has outperformed BIB with an annualized return of 7.72%, while BIB has yielded a comparatively lower 3.60% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
XBI vs. BIB - Expense Ratio Comparison
XBI has a 0.35% expense ratio, which is lower than BIB's 0.95% expense ratio.
Risk-Adjusted Performance
XBI vs. BIB - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and ProShares Ultra Nasdaq Biotechnology (BIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
XBI vs. BIB - Dividend Comparison
XBI's dividend yield for the trailing twelve months is around 0.02%, less than BIB's 0.15% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 0.02% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% | 0.17% |
BIB ProShares Ultra Nasdaq Biotechnology | 0.15% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
XBI vs. BIB - Drawdown Comparison
The maximum XBI drawdown since its inception was -63.89%, roughly equal to the maximum BIB drawdown of -67.24%. Use the drawdown chart below to compare losses from any high point for XBI and BIB. For additional features, visit the drawdowns tool.
Volatility
XBI vs. BIB - Volatility Comparison
The current volatility for SPDR S&P Biotech ETF (XBI) is 7.82%, while ProShares Ultra Nasdaq Biotechnology (BIB) has a volatility of 10.56%. This indicates that XBI experiences smaller price fluctuations and is considered to be less risky than BIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.